S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
The single greatest medical breakthrough of all time? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
The single greatest medical breakthrough of all time? (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
Buy THIS stock before Taiwan is attacked (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
The single greatest medical breakthrough of all time? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
The single greatest medical breakthrough of all time? (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
Buy THIS stock before Taiwan is attacked (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
The single greatest medical breakthrough of all time? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
The single greatest medical breakthrough of all time? (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
Buy THIS stock before Taiwan is attacked (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
The single greatest medical breakthrough of all time? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
The single greatest medical breakthrough of all time? (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
Buy THIS stock before Taiwan is attacked (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
CVE:TLT

Theralase Technologies (TLT) Stock Forecast, Price & News

C$0.24
-0.01 (-4.08%)
(As of 06/5/2023 05:17 PM ET)
Compare
Today's Range
C$0.24
▼
C$0.25
50-Day Range
C$0.23
▼
C$0.28
52-Week Range
C$0.23
▼
C$0.41
Volume
51,772 shs
Average Volume
87,809 shs
Market Capitalization
C$50.88 million
P/E Ratio
N/A
Dividend Yield
1,234.04%
Price Target
N/A
ProfileChartCompetitorsEarningsInsider TradesHeadlinesOptions Chain

TLT stock logo

About Theralase Technologies (CVE:TLT) Stock

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancer, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II for the treatment of Bacillus Calmette Guérin - Unresponsive Carcinoma In-Situ non-muscle invasive bladder cancer. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it provides controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine and therapy; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. It sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1994 and is based in Toronto, Canada.

Receive TLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theralase Technologies and its competitors with MarketBeat's FREE daily newsletter.

TLT Stock News Headlines

May 30, 2023 | finanznachrichten.de
Theralase Technologies Inc.: Theralase Releases 1Q2023 Interim Financial Statements
May 30, 2023 | finanznachrichten.de
Theralase Technologies Inc.: Theralase Releases Corrected and Restated Press Release for 1Q2023 Interim Financial Statements
June 6, 2023 | Behind the Markets (Ad)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
May 30, 2023 | finance.yahoo.com
Theralase(R) Releases 1Q2023 Interim Financial Statements
May 30, 2023 | finance.yahoo.com
Theralase(R) Releases Corrected and Restated Press Release for 1Q2023 Interim Financial Statements
May 24, 2023 | finance.yahoo.com
Theralase(R) Appoints Roger DuMoulin-White as President and Chief Executive Officer
May 22, 2023 | theglobeandmail.com
Closing Bell: Theralase Technologies Inc down on Friday (TLT)
May 17, 2023 | theglobeandmail.com
Closing Bell: Theralase Technologies Inc up on Wednesday (TLT)
June 6, 2023 | Behind the Markets (Ad)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
May 13, 2023 | theglobeandmail.com
Closing Bell: Theralase Technologies Inc WT flat on Friday (TLT-WT)
May 10, 2023 | finanznachrichten.de
Theralase Technologies Inc.: Theralase Provides Update on Phase II Bladder Cancer Study
May 10, 2023 | finance.yahoo.com
Theralase Provides Update on Phase II Bladder Cancer Study
May 9, 2023 | theglobeandmail.com
Closing Bell: Theralase Technologies Inc flat on Monday (TLT)
May 5, 2023 | theglobeandmail.com
Closing Bell: Theralase Technologies Inc up on Thursday (TLT)
May 2, 2023 | theglobeandmail.com
Closing Bell: Theralase Technologies Inc WT flat on Monday (TLT-WT)
May 2, 2023 | theglobeandmail.com
Closing Bell: Theralase Technologies Inc down on Monday (TLT)
April 29, 2023 | finanznachrichten.de
Theralase Technologies Inc.: Theralase Releases FY2022 Audited Financial Statements
April 28, 2023 | theglobeandmail.com
Closing Bell: Theralase Technologies Inc up on Friday (TLT)
April 27, 2023 | theglobeandmail.com
Closing Bell: Theralase Technologies Inc down on Wednesday (TLT)
April 26, 2023 | theglobeandmail.com
Closing Bell: Theralase Technologies Inc down on Tuesday (TLT)
April 26, 2023 | finance.yahoo.com
Theralase® Releases FY2022 Audited Financial Statements
April 26, 2023 | theglobeandmail.com
Closing Bell: Theralase Technologies Inc WT down on Tuesday (TLT-WT)
April 21, 2023 | theglobeandmail.com
Closing Bell: Theralase Technologies Inc down on Thursday (TLT)
April 19, 2023 | theglobeandmail.com
Closing Bell: Theralase Technologies Inc WT flat on Tuesday (TLT-WT)
April 19, 2023 | theglobeandmail.com
Closing Bell: Theralase Technologies Inc WT up on Monday (TLT-WT)
April 15, 2023 | theglobeandmail.com
Closing Bell: Theralase Technologies Inc WT down on Friday (TLT-WT)
April 13, 2023 | theglobeandmail.com
Closing Bell: Theralase Technologies Inc WT up on Wednesday (TLT-WT)
See More Headlines

TLT Price History

TLT Company Calendar

Last Earnings
5/30/2023
Today
6/06/2023
Next Earnings (Estimated)
9/04/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
CVE
Industry
Medical Appliances & Equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
CVE:TLT
CUSIP
N/A
CIK
N/A
Web
theralase.com
Phone
+1-416-6995273
Fax
N/A
Employees
20
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
C($0.02)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
C$-5,240,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-128.27%
Return on Assets
-64.71%

Debt

Debt-to-Equity Ratio
15.31
Current Ratio
3.67
Quick Ratio
3.40

Sales & Book Value

Annual Sales
C$1.14 million
Price / Sales
44.63
Cash Flow
C$0.01 per share
Price / Cash Flow
30.45
Book Value
C$0.01 per share
Price / Book
23.50

Miscellaneous

Outstanding Shares
216,500,000
Free Float
N/A
Market Cap
C$50.88 million
Optionable
Optionable
Beta
1.90

Key Executives

  • Dr. Arkady Mandel DSc.
    M.D., Ph.D., Interim CEO, Chief Scientific Officer & Director
  • Ms. Kristina Hachey CPA
    CFO & Director
  • Mr. David M. Groves B.A
    Pres of World Trade Division
  • Mr. Roger John Dumoulin-White
    Director of Bus. Devel.
  • Lori Leach
    Marketing & Media Relations Consultant
  • Mr. Vaughn Wyant
    Marketing & Media Relations Consultant
  • Dr. Terry Ruch DVM
    Equine Medical Consultant

Key Competitors

View All Competitors













TLT Stock - Frequently Asked Questions

How have TLT shares performed in 2023?

Theralase Technologies' stock was trading at C$0.32 at the start of the year. Since then, TLT stock has decreased by 26.6% and is now trading at C$0.24.
View the best growth stocks for 2023 here.

When is Theralase Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, September 4th 2023.
View our TLT earnings forecast.

How were Theralase Technologies' earnings last quarter?

Theralase Technologies Inc. (CVE:TLT) announced its earnings results on Tuesday, May, 30th. The company reported ($0.01) earnings per share (EPS) for the quarter. The firm had revenue of $0.21 million for the quarter.

Is Theralase Technologies a good dividend stock?

Theralase Technologies (CVE:TLT) pays an annual dividend of C$2.90 per share and currently has a dividend yield of 2.03%.

What other stocks do shareholders of Theralase Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Theralase Technologies investors own include IMRIS (IMRSQ), Cross Timbers Royalty Trust (CRT), Aurora Cannabis (ACB), AGNC Investment (AGNC), InfraCap MLP ETF (AMZA), Alliance Resource Partners (ARLP), Ford Motor (F), Gladstone Investment (GAIN) and Heat Biologics (HTBX).

What is Theralase Technologies' stock symbol?

Theralase Technologies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "TLT."

How do I buy shares of Theralase Technologies?

Shares of TLT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Theralase Technologies' stock price today?

One share of TLT stock can currently be purchased for approximately C$0.24.

How much money does Theralase Technologies make?

Theralase Technologies (CVE:TLT) has a market capitalization of C$50.88 million and generates C$1.14 million in revenue each year. The company earns C$-5,240,000.00 in net income (profit) each year or C($0.02) on an earnings per share basis.

How can I contact Theralase Technologies?

Theralase Technologies' mailing address is 1945 Queen St E, TORONTO, ON M4L 1H7, Canada. The official website for the company is theralase.com. The company can be reached via phone at +1-416-6995273.

This page (CVE:TLT) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -